Insmed Incorporated
INSM
Positions held
Your positionsINSM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Insmed is strategically positioned in the biotechnology sector, focusing on innovative therapies for rare diseases, which can lead to less competition and higher profit margins.
- In Q2 2026, Insmed reported a revenue increase of 39% compared to the prior quarter, reaching $425 million.
- The gross margin for Q2 2026 was 84.2%, indicating strong product profitability despite operational challenges.
- The company has a high debt-to-equity ratio of 97.654, which raises concerns about financial stability and the ability to fund future growth.
- Insmed's operating margin remains negative at -23.8% in Q2 2026, reflecting ongoing challenges in managing operational costs.
- The overall trend shows a 'Strong Sell' signal with a score of -24.00, indicating significant bearish sentiment among analysts.
Fundamentals
| Market cap | $21.94B | Enterprise value | $21.52B | Trailing P/E | — | Forward P/E | 127.61 |
| PEG | 1.09 | Price / book | 28.96 | Beta | 0.82 | Dividend yield | 0.00% |
| Revenue growth | 3.0% | Earnings growth | — | Gross margin | 83.5% | Operating margin | -23.8% |
| Profit margin | -76.9% | ROE | -87.2% | ROA | -22.2% | Debt / equity | 0.98 |
| Current ratio | 3.72 | Free cash flow | -$571.82M | Analyst recommendation | strong_buy | Mean target | $197.74 |
| 52w high | $212.75 | 52w low | $90.39 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $425M | $306M | $264M | $142M | $107M | — |
| Op margin | -23.8% | -65.5% | -94.6% | -183.6% | -236.4% | — |
| Net income | -$13.2M | -$164M | -$328M | -$370M | -$322M | — |
| Gross margin | 84.2% | 84.5% | 83.2% | 79.4% | 73.9% | — |
| Gross profit | $358M | $259M | $220M | $113M | $79.3M | — |
| Operating income | -$101M | -$200M | -$250M | -$261M | -$254M | — |
- Revenue +39% vs prior quarter ($425M vs $306M).
- Gross margin 84.2% (was 84.5% prior quarter).
- Operating margin expanded to -23.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $606M | $364M | $305M | $245M | — |
| Op margin | -164.0% | -216.3% | -223.1% | -194.9% | — |
| Net income | -$1.3B | -$914M | -$750M | -$482M | — |
| Gross margin | 79.7% | 76.4% | 78.5% | 77.5% | — |
| Gross profit | $483M | $278M | $240M | $190M | — |
| Operating income | -$995M | -$787M | -$681M | -$478M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?
2026-10-07 · Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
2026-10-06 · INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
2026-10-05 · Insmed stock falls as CFO Sara Bonstein to step down
2026-10-05 · Sector Update: Healthcare Stocks Steady Pre-Bell Monday
2026-10-05 · Insmed Chief Financial Officer Sara Bonstein to Step Down
2026-10-05 · Insmed Announces CFO Transition
2026-10-01 · Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
2026-09-28 · Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?
2026-09-25 · What BioPharma Credit (BPCP) Said on Its H1 Earnings Call
2026-09-23 · Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
2026-09-22 · FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
Price (daily)
Full chart · RSI · MACD · patterns